Harvard Bioscience Inc. reported preliminary fourth quarter (Q4) 2025 revenue of USD 23.7 million, which was above the midpoint of its guidance range of USD 22.5 million to USD 24.5 million. The company expects a gross margin of 60% for the period, at the high end of its guidance, supported by an improved mix toward higher margin product lines and the impact of previous cost reduction initiatives. Adjusted EBITDA for Q4 2025 is expected to be USD 3.8 million, reflecting 27% growth year over year. Harvard Bioscience Inc. outlined its long-term strategy focused on strengthening its position in the translational science tools market, expanding consumables revenue, and enhancing operational performance. Management indicated confidence in achieving year over year revenue growth and mid-to high-single-digit adjusted EBITDA growth in 2026. The CEO noted the company’s progress following refinancing and strategic consolidation, and highlighted continued efforts to align business priorities with evolving life sciences industry needs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651631-en) on February 10, 2026, and is solely responsible for the information contained therein.